May be taken with or without food. Swallow the tablet whole with a glass of water.

Amlosartan inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It is a dihydropyridine calcium antagonist (calcium ion antagonist or slow channel blocker) that inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. The contractile process of cardiac muscle and vascular smooth muscle depends upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlosartan inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. This relaxation of vascular smooth muscle reduces peripheral vascular resistance, leading to a reduction in blood pressure.

• •Hypersensitivity to Amlosartan or other dihydropyridines
• •Severe hypotension
• •Cardiogenic shock
• •Obstructive outflow tract disease (e.g., severe aortic stenosis)
• •Unstable angina pectoris (excluding Prinzmetal's angina)

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Symptoms of overdose include excessive peripheral vasodilation with marked hypotension and possibly a reflex tachycardia. Management involves symptomatic treatment and supportive measures. Clinically significant hypotension may require active cardiovascular support, including elevation of extremities, fluid administration, and vasopressors if appropriate. Calcium gluconate may be beneficial to reverse the effects of calcium channel blockade.

Pregnancy Category C. Amlosartan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether amlosartan is excreted in human milk. Caution should be exercised when amlosartan is administered to a nursing woman.